This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Parecoxib sodium, Dynastat, Rayzon, Xapit, YM978
Description: Parecoxib sodium is the injectable prodrug to Bextra (valdecoxib), which is a longer acting non-steroidal antiinflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties. These effects are due to the inhibition of COX-2, which in turn inhibits prostaglandin synthesis.
Deal Structure: In May 2004, Yamanouchi Pharmaceutical Co., Ltd. reached a new agreement with Pfizer in order to restructure the existing partnership on COX-2 inhibitors in clinical development in Japan. Yamanouchi and Pfizer reaffirmed that they will co-develop and co-promote the COX-2 inhibitor compounds valdecoxib (Bextra) and parecoxib in Japan. The arrangements will be similar to the existing arrangements for celecoxib (Celebrex). The valdecoxib and parecoxib compounds will be co-developed by Yamanouchi and Pfizer, distributed by Yamanouchi and co-promoted by the two companies under a single brand name in Japan.
On April 1, 2005, Astellas Pharma was formed from a merger between Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.
Partners: Astellas Pharma, Inc.
Pink Sheet Safety Announcements
Pink Sheet Parecoxib perishes?
Pink Sheet Pfizer parecoxib "not approvable"
Additional information available to subscribers only: